CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?

Affiliations

¹ Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: sara_tolaney@dfci.harvard.edu.

Comment

Shom Goel et al. Lancet Oncol. 2019 Nov.

. 2019 Nov;20(11):1479-1481.

doi: 10.1016/S1470-2045(19)30627-8. Epub 2019 Sep 28.

¹ Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: sara_tolaney@dfci.harvard.edu.

No abstract available

Comment on

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Yang Z, Antal JM, Morris SR, O'Shaughnessy J. Tan AR, et al. Lancet Oncol. 2019 Nov;20(11):1587-1601. doi: 10.1016/S1470-2045(19)30616-3. Epub 2019 Sep 28. Lancet Oncol. 2019. PMID: 31575503 Clinical Trial.